COVID-19 and its relationship with hypertension and cardiovascular disease
Copyright © 2020 SEH-LELHA. Publicado por Elsevier España, S.L.U. All rights reserved..
The association between hypertension, diabetes, cardio and cerebrovascular disease and severe and fatal COVID-19, described in different countries, is remarkable. Myocardial damage and myocardial dysfunction are postulated as a possible causal nexus. Frequent findings of elevated troponin levels and electrocardiographic anomalies support this concept. On the other hand, hypotheses in favour and against a deleterious effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers, a usual treatment for cardiovascular disease, have been raised. There is currently no solid evidence and thus properly designed studies on this subject are urgently needed. In this context, patients with cardiovascular disease should especially avoid being exposed to the virus, should not self-medicate and rapidly seek medical advice should they show symptoms of infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Hipertension y riesgo vascular - 37(2020), 4 vom: 23. Okt., Seite 176-180 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
COVID-19, hipertensión y enfermedad cardiovascular |
|---|
| Beteiligte Personen: |
Salazar, M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.10.2020 Date Revised 19.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.hipert.2020.06.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311694888 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311694888 | ||
| 003 | DE-627 | ||
| 005 | 20231225142812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.hipert.2020.06.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311694888 | ||
| 035 | |a (NLM)32591283 | ||
| 035 | |a (PII)S1889-1837(20)30065-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Salazar, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 and its relationship with hypertension and cardiovascular disease |
| 246 | 3 | 3 | |a COVID-19, hipertensión y enfermedad cardiovascular |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2020 | ||
| 500 | |a Date Revised 19.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 SEH-LELHA. Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a The association between hypertension, diabetes, cardio and cerebrovascular disease and severe and fatal COVID-19, described in different countries, is remarkable. Myocardial damage and myocardial dysfunction are postulated as a possible causal nexus. Frequent findings of elevated troponin levels and electrocardiographic anomalies support this concept. On the other hand, hypotheses in favour and against a deleterious effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers, a usual treatment for cardiovascular disease, have been raised. There is currently no solid evidence and thus properly designed studies on this subject are urgently needed. In this context, patients with cardiovascular disease should especially avoid being exposed to the virus, should not self-medicate and rapidly seek medical advice should they show symptoms of infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cardiovascular disease | |
| 650 | 4 | |a Enfermedad cardiovascular | |
| 650 | 4 | |a High blood pressure | |
| 650 | 4 | |a Hipertensión arterial | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Pronóstico | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Angiotensin II Type 1 Receptor Blockers |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Receptors, Virus |2 NLM | |
| 650 | 7 | |a Peptidyl-Dipeptidase A |2 NLM | |
| 650 | 7 | |a EC 3.4.15.1 |2 NLM | |
| 650 | 7 | |a ACE2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 700 | 1 | |a Barochiner, J |e verfasserin |4 aut | |
| 700 | 1 | |a Espeche, W |e verfasserin |4 aut | |
| 700 | 1 | |a Ennis, I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hipertension y riesgo vascular |d 2015 |g 37(2020), 4 vom: 23. Okt., Seite 176-180 |w (DE-627)NLM250932563 |x 1989-4805 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g number:4 |g day:23 |g month:10 |g pages:176-180 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.hipert.2020.06.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |e 4 |b 23 |c 10 |h 176-180 | ||